3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
36
Leukemia
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Gastrointestinal Stromal Tumors
13
Leukemia, Myeloid, Chronic-Phase
12
Leukemia, Myeloid
6
Brain Neoplasms
6
Prostatic Neoplasms
5
Philadelphia Chromosome
5
Blast Crisis
5
Sarcoma
4
Recurrence
4
Glioblastoma
4
Carcinoma, Non-Small-Cell Lung
4
Bone Marrow Diseases
4
Ovarian Neoplasms
3
Melanoma
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Hematologic Diseases
3
Bronchiolitis Obliterans Syndrome
3
Breast Neoplasms
3
Stomach Neoplasms
2
Polycythemia Vera
2
Neurofibromatoses
2
Neoplasms by Histologic Type
2
Neoplasms
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Meningioma
2
Interventions
mirdametinib
2
tipifarnib
1
peginterferon alfa-2b
1
nilotinib
1
binimetinib
1
Vincristine
1
Temozolomide
1
Radiosurgery
1
Imatinib Mesylate
1
Everolimus
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neurofibroma
×
Imatinib Mesylate
×
Clear all
NCT01140360
2017-07-02
0908-09
Indiana University
Phase 1/2
Completed
21 enrolled
8 charts